Contraindications for Citalopram (Celexa)
Citalopram is absolutely contraindicated with MAOIs, pimozide, and in patients with known hypersensitivity to the drug. 1
Absolute Contraindications
Based on FDA labeling and clinical guidelines, the following are strict contraindications for citalopram:
1. Monoamine Oxidase Inhibitors (MAOIs)
- Concomitant use with MAOIs is contraindicated due to severe risk of serotonin syndrome, which can be fatal 1
- This includes phenelzine, isocarboxazid, moclobemide, isoniazid, and linezolid 2
- Critical timing: Do not use citalopram within 14 days of discontinuing an MAOI 1
- Serotonin syndrome manifests with mental status changes (confusion, agitation), neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity), and autonomic hyperactivity (hypertension, tachycardia, arrhythmias) 2
- Advanced symptoms include fever, seizures, arrhythmias, and unconsciousness leading to death 2
2. Pimozide
- Absolute contraindication due to pharmacodynamic interaction 1
- Co-administration causes QTc prolongation of approximately 10 msec, increasing risk of torsades de pointes 1
3. Known Hypersensitivity
- Contraindicated in patients with hypersensitivity to citalopram or any inactive ingredients 1
Critical Warnings and High-Risk Situations
Long QT Syndrome and QTc Prolongation
- Avoid citalopram in patients with congenital long QT syndrome 2
- Citalopram causes dose-dependent QTc prolongation associated with torsades de pointes, ventricular tachycardia, and sudden death 2
- Maximum dose restrictions: Do not exceed 40 mg/day in adults; reduce to 20 mg/day maximum in patients >60 years old 3
- Exercise extreme caution when combining with other QTc-prolonging drugs 2
Uncontrolled Hypertension
- While not an absolute contraindication for citalopram alone, naltrexone/bupropion ER (which contains bupropion) is contraindicated in uncontrolled hypertension 4, 5
- Abrupt citalopram discontinuation can paradoxically cause new-onset hypertension 6
Drug Interactions Requiring Extreme Caution
Serotonergic drugs - High risk of serotonin syndrome when combined with:
- Other SSRIs, SNRIs, TCAs 2
- Triptans (sumatriptan, etc.) - monitor closely for weakness, hyperreflexia, incoordination 1
- Tramadol, meperidine, methadone, fentanyl 2
- Dextromethorphan, St. John's Wort, L-tryptophan 2
- Lithium - enhances serotonergic effects; monitor lithium levels 1
Drugs affecting hemostasis:
- NSAIDs, aspirin, warfarin increase bleeding risk 1
- Monitor INR closely when initiating or discontinuing citalopram in patients on warfarin 1
Special Populations
Pregnancy and Breastfeeding
- Patients should notify physician if pregnant, planning pregnancy, or breastfeeding 1
- All weight management medications containing antidepressants are contraindicated in pregnancy 5
Elderly Patients (>60 years)
- Maximum dose reduced to 20 mg/day due to increased QTc prolongation risk 3
- Higher risk of cardiac arrest (OR 1.21 for SSRIs) 3
Seizure Disorders
Regarding "Coercitan"
Coercitan is not a recognized medication name in standard pharmaceutical databases or FDA-approved drug lists. This may be:
- A misspelling or regional name for another medication
- A compounded or non-FDA approved product
- A medication available outside the United States
Without identification of what "Coercitan" actually contains, no specific contraindications can be provided. If this is a combination product or alternative name, clarification of its active ingredients is essential before assessing contraindications with citalopram.
Clinical Pitfalls to Avoid
- Do not abruptly discontinue citalopram - can cause withdrawal syndrome (dizziness, nausea, anxiety, irritability) and new-onset hypertension 6
- Screen baseline ECG in patients with cardiac risk factors or on QTc-prolonging drugs 3
- Monitor closely in first 1-2 weeks for suicidal ideation, especially in patients <24 years 1
- Avoid alcohol during treatment 1
- Watch for sexual dysfunction in adolescents and adults - common but underreported 2